SWITCHING FROM INTRACAVERNOUS PROSTAGLANDIN E1 INJECTIONS TO ORAL SILDENAFIL CITRATE IN PATIENTS WITH ERECTILE DYSFUNCTION: RESULTS OF A MULTICENTER EUROPEAN STUDY

Abstract

No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Sep 2000SWITCHING FROM INTRACAVERNOUS PROSTAGLANDIN E1 INJECTIONS TO ORAL SILDENAFIL CITRATE IN PATIENTS WITH ERECTILE DYSFUNCTION: RESULTS OF A MULTICENTER EUROPEAN STUDY FRANÇOIS GIULIANO, FRANCESCO MONTORSI, VINCENZO MIRONE, DOMINIQUE ROSSI, MICHAEL SWEENEY, and for the Sildenafil Multicenter Study Group∥ FRANÇOIS GIULIANOFRANÇOIS GIULIANO More articles by this author , FRANCESCO MONTORSIFRANCESCO MONTORSI More articles by this author , VINCENZO MIRONEVINCENZO MIRONE More articles by this author , DOMINIQUE ROSSIDOMINIQUE ROSSI More articles by this author , MICHAEL SWEENEYMICHAEL SWEENEY More articles by this author , and for the Sildenafil Multicenter Study Group∥ More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)67286-2AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Intracavernous injection is a well established medical therapy for erectile dysfunction. We assessed the rate of success when patients with erectile dysfunction who were effectively treated with intracavernous injections of prostaglandin E1 were changed to oral therapy with sildenafil citrate. Materials and Methods: Only patients effectively managing erectile dysfunction by the intracavernous injection of 20 μg. or less prostaglandin E1 for more than 6 months were eligible for study enrollment. After a 4-week run-in phase while intracavernous prostaglandin E1 therapy continued and a 48-hour washout period 176 patients with erectile dysfunction received open label sildenafil orally for 12 weeks. Satisfaction with treatment was evaluated by the 11-item erectile dysfunction index of treatment satisfaction questionnaire. A successful change to sildenafil was prospectively defined as a questionnaire score of 0 to 100 after sildenafil that was greater than or equal to the score after intracavernous prostaglandin E1. Results: Of the 176 patients 69% (95% confidence limit 62 to 76) successfully changed from intracavernous prostaglandin E1 injections to oral sildenafil and elected to continue oral treatment. Mean satisfaction score after sildenafil and prostaglandin E1 was 73.8 and 63.9, respectively (p <0.001). Only 3 patients (1.7%) discontinued therapy because of treatment related adverse events. Conclusions: More than two-thirds of the men with erectile dysfunction who were stable on intracavernous injections of 20 μg. or less prostaglandin E1 successfully changed to oral sildenafil, as determined by maintained or enhanced treatment satisfaction. References 1 : Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies. Urology1999; 53: 1011. Google Scholar 2 : Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med1998; 338: 1397. Google Scholar 3 : Randomized trial of sildenafil for the treatment of erectile dysfunction in spinal cord injury. Sildenafil Study Group. Ann Neurol1999; 46: 15. Google Scholar 4 : Outcome analysis of goal directed therapy for impotence. J Urol1996; 155: 1609. Link, Google Scholar 5 : Clinical Guidelines Panel on Erectile Dysfunction: summary report on the treatment of organic erectile dysfunction. J Urol1996; 156: 2007. Link, Google Scholar 6 : Intracavernous Alprostadil Alfadex—an effective and well tolerated treatment for erectile dysfunction. Results of a long-term European study. Int J Impot Res1998; 10: 225. Google Scholar 7 Report on the Treatment of Organic Erectile Dysfunction AUA Erectile Dysfunction Panel. Baltimore, Maryland: American Urological Association, Inc.1996. Google Scholar 8 : Predictors of success and risk factors for attrition in the use of intracavernous injection. J Urol1997; 157: 1681. Link, Google Scholar 9 : High attrition rate with intracavernous injection of prostaglandin E1 for impotency. Urology1994; 43: 84. Google Scholar 10 : Intracavernosal self-injection therapy in men with erectile dysfunction: satisfaction and attrition in 119 patients. Int J Impot Res1999; 11: 145. Google Scholar 11 : Comparison of long-term outcomes of penile prostheses and intracavernosal injection therapy. J Urol1998; 159: 811. Link, Google Scholar 12 : EDITS: development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology1999; 53: 793. Google Scholar 13 : The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology1997; 49: 822. Google Scholar 14 : Injectable drugs: advantages and drawbacks. In: . London: Martin Dunitz Ltd1998: 157. Google Scholar 15 : Experience with intracavernous PGE-1 in the treatment of erectile dysfunction: dose considerations and efficacy. Int J Impot Res1997; 9: 39. Google Scholar 16 : Reasons for high drop-out rate with self-injection therapy for impotence. Int J Impot Res1994; 6: 171. Google Scholar 17 : Long-term follow-up of patients receiving injection therapy for erectile dysfunction. Urology1997; 49: 932. Google Scholar 18 : Long-term safety and efficacy after 2 years of Viagra (sildenafil citrate) treatment in erectile dysfunction. J Urol1999; 161: 214. abstract 819. Google Scholar 19 : Sildenafil (VIAGRA™), an oral treatment for erectile dysfunction: a 1-year, open-label, extension study. J Urol1997; 157: 204. abstract 793. Google Scholar 20 The process of care model for evaluation and treatment of erectile dysfunction Process of Care Consensus Panel. Int J Impot Res1999; 11: 59. Google Scholar From the Department of Urology, CHU de Bicêtre, AP-HP Le Kremlin Bicêtre and Hôpital Salvator, Marseille, France, Istituto San Raffaele, Milan and Università di Napoli Federico II, Napoli, Italy, and Pfizer, Inc., New York, New York© 2000 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byRAJPURKAR A and DHABUWALA C (2018) Comparison of Satisfaction Rates and Erectile Function in Patients Treated with Sildenafil, Intracavernous Prostaglandin E1 and Penile Implant Surgery for Erectile Dysfunction in Urology PracticeJournal of Urology, VOL. 170, NO. 1, (159-163), Online publication date: 1-Jul-2003.STEERS W (2018) Viability and Safety of Combination Drug Therapies for Erectile DysfunctionJournal of Urology, VOL. 170, NO. 2S, (S20-S23), Online publication date: 1-Aug-2003. Volume 164Issue 3 Part 1September 2000Page: 708-711 Advertisement Copyright & Permissions© 2000 by American Urological Association, Inc.Keywordspenile erectionimpotencepenisalprostadilpatient satisfactionMetricsAuthor Information FRANÇOIS GIULIANO More articles by this author FRANCESCO MONTORSI More articles by this author VINCENZO MIRONE More articles by this author DOMINIQUE ROSSI More articles by this author MICHAEL SWEENEY More articles by this author for the Sildenafil Multicenter Study Group∥ More articles by this author Expand All Advertisement PDF downloadLoading ...